Ipca Laboratories announced that its manufacturing facility in Tarapur (Palghar-Maharashtra) has received an Establishment Inspection Report classifying the facility as Voluntary Action Indicated (VAI). This indicates the facility is considered to be in a minimally acceptable state of compliance with current good manufacturing practice (CGMP) standards. The US FDA inspected the facility between December 1st and 5th, 2025.
Tarapur Facility Update
Ipca Laboratories has received the Establishment Inspection Report for its Active Pharmaceutical Ingredients (API) manufacturing facility situated in Tarapur. The inspection was conducted by the US FDA from December 1st to 5th, 2025.
Voluntary Action Indicated Classification
The inspection report classifies the Tarapur manufacturing facility as having achieved “Voluntary Action Indicated (VAI)” status. This means that the facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP). The company considers this to be a positive outcome from the inspection.
Source: BSE
